Cargando…
BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding
In this study, we report BF066, a novel adenine derivative, inhibits platelet activation and thrombosis via the adenosine receptor (A(2A)) activation and phosphodiesterase (PDE) inhibition. BF066 inhibits platelet aggregation and ATP releasing induced by multiple platelet agonists in a dose-dependen...
Autores principales: | Pan, ChangE, Wei, Xunbin, Ye, Jianqin, Liu, Guangda, Zhang, Si, Zhang, Yan, Du, Hongguang, Ding, Zhongren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398006/ https://www.ncbi.nlm.nih.gov/pubmed/22815749 http://dx.doi.org/10.1371/journal.pone.0040451 |
Ejemplares similares
-
Post-ERCP Bleeding in the Era of Multiple Antiplatelet Agents
por: Oh, Hyoung-Chul, et al.
Publicado: (2018) -
Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding
por: Carlin, Neal, et al.
Publicado: (2017) -
Magnetostructural transformation and magnetocaloric effect of Sn-bonded Mn(0.66)Fe(0.34)Ni(0.66)Fe(0.34)Si(0.66)Ge(0.34) composite
por: Si, Yu, et al.
Publicado: (2018) -
P066 Abstract Withdrawn
Publicado: (2021) -
Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed
por: Gosavi, Siddharth, et al.
Publicado: (2023)